Intraneuronal dopamine-quinone synthesis: a review

α-Synuclein in Lewy bodies

Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · see citing works

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · see citing works

Histochemistry: Theoretical and Applied

(1953) · JAMA · doi:10.1001/jama.1953.02940280072039 · Cited by 7,021 · see citing works

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · see citing works

AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836 · see citing works

Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

(1998) · Europe PMC (PubMed Central) · Cited by 1,594 · see citing works

Tyrosinase: a comprehensive review of its mechanism

Sánchez‐Ferrer, Á., Rodríguez‐López, J. N., Garcı́a-Cánovas, F., & García‐Carmona, F. (1995) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(94)00204-t · Cited by 1,244 · see citing works

Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones

GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126 · cited 4× · see citing works

Oxidative stress and the pathogenesis of Parkinson's disease

Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971 · see citing works

The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it

Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927 · see citing works

Degradation of oxidized proteins in mammalian cells

Grune, T., Reinheckel, T., & Davies, K. J. A. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.7.9212076 · Cited by 835 · see citing works

Amphetamine: Effects on Catecholamine Systems and Behavior

Seiden, L. S., Sabol, K. E., & Ricaurte, G. A. (1993) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.33.040193.003231 · Cited by 821 · see citing works

Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport

Sulzer, D., Chen, T., Lau, Y., Kristensen, H., Rayport, S., & Ewing, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-04102.1995 · Cited by 688 · see citing works

Frameshift Mutants of β Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients

van Leeuwen, F. W., de Kleijn, D. P. V., van den Hurk, H., Neubauer, A., Sonnemans, M. A. F., Sluijs, J. A., Köycü, S., Ramdjielal, R. D. J., Salehi, A., Martens, G. J. M., et al. (1998) · Science · doi:10.1126/science.279.5348.242 · Cited by 561 · see citing works

Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione System

Spina, M. B., Squinto, S. P., Miller, J. M., Lindsay, R. M., & Hyman, C. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08880.x · Cited by 460 · see citing works

Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

Przedborski, S., Kostić, V., Jackson-Lewis, V. R., Naini, A. B., Simonetti, S., Fahn, S., Carlson, E. J., Epstein, C. J., & Cadet, J. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01658.1992 · Cited by 456 · see citing works

Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine

LaVoie, M. J., & Hastings, T. G. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01484.1999 · Cited by 449 · see citing works

Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress

Cubells, J. F., Rayport, S., Rajendran, G., & Sulzer, D. L. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-04-02260.1994 · Cited by 448 · see citing works

Histochemistry. Theoretical and Applied

Bitensky, L. (1985) · Journal of Clinical Pathology · doi:10.1136/jcp.38.10.1200-c · Cited by 424 · see citing works

Real-time measurement of transmitter release from single synaptic vesicles

Bruns, D., & Jahn, R. (1995) · Nature · doi:10.1038/377062a0 · Cited by 407 · see citing works

Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.

Takeda, A., Mallory, M. E., Sundsmo, M. P., Honer, W. G., Hansen, L. A., & Masliah, E. (1998) · Europe PMC (PubMed Central) · Cited by 404 · see citing works

Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinsonʼs Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity

Irizarry, M. C., Growdon, W., Gómez‐Isla, T., Newell, K. L., George, J. M., Clayton, D. F., & Hyman, B. T. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199804000-00005 · Cited by 394 · see citing works

Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action

Sulzer, D., & Rayport, S. (1990) · Neuron · doi:10.1016/0896-6273(90)90339-h · Cited by 389 · see citing works

Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase

Hastings, T. G. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020919.x · Cited by 359 · see citing works

Ubiquitin carboxyl‐terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases

Lowe, J. S., McDermott, H., Landon, M., Mayer, R. J., & Wilkinson, K. D. (1990) · The Journal of Pathology · doi:10.1002/path.1711610210 · Cited by 359 · see citing works

PHASE AND ELECTRON MICROSCOPIC OBSERVATIONS OF LEWY BODIES AND MELANIN GRANULES IN THE SUBSTANTIA NIGRA AND LOCUS CAERULEUS IN PARKINSONʼS DISEASE

Duffy, P. E., & Tennyson, V. M. (1965) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196507000-00003 · Cited by 351 · see citing works

Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture

Michel, P. P., & Hefti, F. F. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490260405 · Cited by 339 · see citing works

NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease

Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M., & Takahashi, H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00891-4 · Cited by 331 · see citing works

Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport

Johnson, R. G. (1988) · Physiological Reviews · doi:10.1152/physrev.1988.68.1.232 · Cited by 323 · see citing works

Presynaptic Recording of Quanta from Midbrain Dopamine Neurons and Modulation of the Quantal Size

Pothos, E. N., Davila, V., & Sulzer, D. L. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-11-04106.1998 · Cited by 320 · see citing works

Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease

Castellani, R. J., Smith, M. A., Richey, G. L., & Perry, G. L. (1996) · Brain Research · doi:10.1016/0006-8993(96)00729-9 · Cited by 315 · see citing works

Selectivity of the Parkinsonian Neurotoxin MPTP: Toxic Metabolite MPP + Binds to Neuromelanin

D’Amato, R. J., Lipman, Z. P., & Snyder, S. H. (1986) · Science · doi:10.1126/science.3080808 · Cited by 296 · see citing works

Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease.

Dg, G. (1984) · PubMed · Cited by 292 · see citing works

Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration

Ben‐Shachar, D., Zuk, R., & Glinka, Y. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020718.x · Cited by 288 · see citing works

Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic Mice

Cadet, J. L., Sheng, P., All, S., Rothman, R. B., Carlson, E. J., & Epstein, C. J. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010380.x · Cited by 263 · see citing works

Lewy Bodies of Parkinson's Disease Contain Neurofilament Antigens

Goldman, J. E., Yen, S.-H. C., Chiu, F., & Peress, N. S. (1983) · Science · doi:10.1126/science.6308771 · Cited by 260 · see citing works

Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Walkinshaw, G., & Waters, C. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117946 · Cited by 242 · see citing works

Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice

Fumagalli, F., Gainetdinov, R. R., Wang, Y., Valenzano, K. J., Miller, G. W., & Caron, M. G. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02424.1999 · Cited by 241 · see citing works

Amyloid β-Protein Inhibits Ubiquitin-dependent Protein Degradation in Vitro

Gregori, L. L., Fuchs, C., Figueiredo‐Pereira, M. E., Nostrand, W. E. V., & Goldgaber, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19702 · Cited by 232 · see citing works

Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson’s disease

Merad-Boudia, M., Nicole, A., Santiard-Baron, D., Saillé, C., & Ceballos-Picot, I. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00647-3 · Cited by 227 · see citing works

Substrate Binding and Catalysis by Ubiquitin C-Terminal Hydrolases: Identification of Two Active Site Residues

Larsen, C. N., Price, J. S., & Wilkinson, K. D. (1996) · Biochemistry · doi:10.1021/bi960099f · Cited by 219 · see citing works

Immunocytochemical Co-localization of the Proteasome in Ubiquitinated Structures in Neurodegenerative Diseases and the Elderly

Ii, K., Ito, H., Tanaka, K., & Hirano, A. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199702000-00002 · Cited by 215 · see citing works

Catecholamine toxicity in cerebral cortex in dissociated cell culture

Rosenberg, P. A. (1988) · Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02887.1988 · Cited by 209 · see citing works

Tyrosine mRNA is expressed in human substantia nigra

Xu, Y., Stokes, A. H., Freeman, W. M., Kumer, S. C., Vogt, B. A., & Vrana, K. E. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00308-7 · Cited by 205 · see citing works

Interaction of neuromelanin and iron in substantia nigra and other areas of human brain

Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G. A., Gerbasi, R., Sarna, T., & Swartz, H. M. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00047-4 · Cited by 197 · see citing works

Ubiquitin in Neurodegenerative Diseases

Lowe, J. S., Mayer, R. J., & Landon, M. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00726.x · Cited by 170 · see citing works

Identification of Catechol‐Protein Conjugates in Neostriatal Slices Incubated with [3H]Dopamine: Impact of Ascorbic Acid and Glutathione

Hastings, T. G., & Zigmond, M. J. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63031126.x · Cited by 168 · see citing works

Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain

Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., & Sabbioni, E. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031097.x · Cited by 163 · see citing works

The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra

Fornstedt, B., Brun, A., Rosengren, E., & Carlsson, A. (1989) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02263482 · Cited by 160 · see citing works

Oxidative damage caused by free radicals produced during catecholamine autoxidation: Protective effects of O-methylation and melatonin

Miller, J. W., Selhub, J., & Joseph, J. A. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(96)00033-0 · Cited by 157 · see citing works

Detection of 5-S-cysteinyldopamine in human brain

Rosengren, E., Linder-Eliasson, E., & Carlsson, A. (1985) · Journal of Neural Transmission · doi:10.1007/bf01252029 · Cited by 152 · see citing works

Prostaglandin H Synthetase‐Mediated Metabolism of Dopamine: Implication for Parkinson's Disease

Mattammal, M. B., Strong, R., Lakshmi, V. M., Chung, H. D., & Stephenson, A. H. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041645.x · Cited by 151 · see citing works

Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?

Prigent, A., Karlsson, J., Agid, Y., & Hirsch, É. C. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00100-5 · Cited by 149 · see citing works

The neuromelanin of the human substantia nigra

Carstam, R., Brinck, C., Hindemith, A., Rorsman, H., & Rosengren, E. (1991) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(91)90100-n · Cited by 142 · see citing works

New insights into the mechanisms and importance of the proteasome in intracellular protein degradation.

Goldberg, A. L., Akopian, T. N., Kisselev, A. F., Lee, D. H., & Rohrwild, M. (1997) · PubMed · Cited by 141 · see citing works

Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells.

Liu, Y., Schweitzer, E. S., Nirenberg, M. J., Pickel, V. M., Evans, C. J., & Edwards, R. H. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.127.5.1419 · Cited by 140 · see citing works

An Antigenic Profile of Lewy Bodies: Immunocytochemical Indication for Protein Phosphorylation and Ubiquitination

Bancher, C., Lassmann, H., Budka, H., Jellinger, K. A., Grundke, I., Iqbal, K., Wiche, G., SEITELBERGER, F., & Wisniewski, H. M. (1989) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198901000-00007 · Cited by 139 · see citing works

Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease

McRitchie, D. A., Cartwright, H., & Halliday, G. M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6418 · Cited by 135 · see citing works

Iron-Mediated Generation of the Neurotoxin 6-Hydroxydopamine Quinone by Reaction of Fatty Acid Hydroperoxides with Dopamine: A Possible Contributory Mechanism for Neuronal Degeneration in Parkinson's Disease

Pezzella, A., d’Ischia, M., Napolitano, A., Misuraca, G., & Prota, G. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970099t · Cited by 133 · see citing works

On the Nature of Pigment Granules in the Cells of the Locus Coeruleus and Substantia Nigra

Foley, J. M., & Banter, D. (1958) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-195810000-00005 · Cited by 129 · see citing works

Effects of L-Cysteine on the Oxidation Chemistry of Dopamine: New Reaction Pathways of Potential Relevance to Idiopathic Parkinson's Disease

Zhang, F., & Dryhurst, G. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00034a006 · Cited by 129 · see citing works

Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5.

Brion, J., & Couck, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 125 · see citing works

Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease

Jicha, G. A., Berenfeld, B., & Davies, P. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990315)55:6 · Cited by 123 · see citing works

DOPAMINE-INDUCED APOPTOSIS IN HUMAN NEURONAL CELLS: INHIBITION BY NUCLEIC ACIDS ANTISENSE TO THE DOPAMINE TRANSPORTER

Simantov, R., BLINDER, E., Ratovitski, T., TAUBER, M., GABBAY, M., & Porat, S. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00102-9 · Cited by 123 · see citing works

Acta Médica Portuguesa

Oliveira, J. C., Macedo, M. M., Luís, A. S., & Galvão-Teles, A. (2022) · Acta Médica Portuguesa · doi:10.20344/amp.5829 · Cited by 116 · see citing works

Catecholamines oxidation by xanthine oxidase

Foppoli, C., Coccia, R., Cini, C., & Rosei, M. A. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00093-1 · Cited by 116 · see citing works

Disproportionation During Electrooxidation of Catecholamines at Carbon-Fiber Microelectrodes

Ciolkowski, E. L., Maness, K. M., Cahill, P. S., Wightman, R. M., Evans, D. H., Fosset, B., & Amatore, C. A. (1994) · Analytical Chemistry · doi:10.1021/ac00093a013 · Cited by 115 · see citing works

Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: Accumulation in neuromelanin

Lindquist, N. G., Larsson, B. S., & Lydén‐Sokolowski, A. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90002-x · Cited by 114 · see citing works

Covalent binding of catechols to proteins through the sulphydryl group

Ito, S., Kato, T., & Fujita, K. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90432-7 · Cited by 114 · see citing works

Proteasome inactivation upon aging and on oxidation-effect of HSP 90

Conconi, M., & Friguet, B. (1997) · Molecular Biology Reports · doi:10.1023/a:1006852506884 · Cited by 111 · see citing works

Irreversible Inhibition of Mitochondrial Complex I by 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1): A Putative Nigral Endotoxin of Relevance to Parkinson's Disease

Li, H., & Dryhurst, G. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041530.x · Cited by 110 · see citing works

New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain

Tief, K., Schmidt, A., & Beermann, F. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00301-x · Cited by 105 · see citing works

Iron- and Manganese-Catalyzed Autoxidation of Dopamine in the Presence of l -Cysteine: Possible Insights into Iron- and Manganese-Mediated Dopaminergic Neurotoxicity

Shen, X.-M., & Dryhurst, G. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980036t · Cited by 104 · see citing works

The chemical characterization of melanin contained in substantia nigra of human brain

Zecca, L., Mecacci, C., Seraglia, R., & Parati, E. A. (1992) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(92)90144-c · Cited by 101 · see citing works

Oxidation and Nitration of Catecholamines by Nitrogen Oxides Derived from Nitric Oxide

Daveu, C., Servy, C., Dendane, M., Marin, P., & Ducrocq, C. (1997) · Nitric Oxide · doi:10.1006/niox.1997.0123 · Cited by 101 · see citing works

Dopamine, tremor, and Parkinson's disease.

Hirsch, E. C., Mouatt, A., Faucheux, B., Bonnet, A., Graybiel, A., & Agid, Y. (1992) · The Lancet · doi:10.1016/0140-6736(92)90457-e · Cited by 97 · see citing works

Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease.

Bertrand, E., Lechowicz, W., Szpak, G. M., & Dymecki, J. (1997) · PubMed · Cited by 95 · see citing works

Generation of the Neurotoxin 6-Hydroxydopamine by Peroxidase/H2O2 Oxidation of Dopamine

Napolitano, A., Crescenzi, O., Pezzella, A., & Prota, G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00006a010 · Cited by 95 · see citing works

Autoxidation of dopamine: A comparison of luminescent and spectrophotometric detection in basic solutions

Klegeris, A., Korkina, L. G., & Greenfield, S. A. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)00141-6 · Cited by 90 · see citing works

Oxidation of Dopamine in the Presence of Cysteine: Characterization of New Toxic Products

Shen, X.-M., Fa, Z., & Dryhurst, G. (1997) · Chemical Research in Toxicology · doi:10.1021/tx960145c · Cited by 86 · see citing works

The role of iron in senescence of dopaminergic neurons in Parkinson's disease.

Youdim, M. B. H., & Riederer, P. (1993) · PubMed · Cited by 83 · see citing works

p35 nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease

Nakamura, S., Kawamoto, Y., Nakano, S., Akiguchi, I., & Kimura, J. (1997) · Acta Neuropathologica · doi:10.1007/s004010050687 · Cited by 82 · see citing works

Chaperoning brain diseases

Welch, W. J., & Gambetti, P. L. (1998) · Nature · doi:10.1038/32049 · Cited by 80 · see citing works

Dopamine and Iron Induce Apoptosis in PC12 Cells

Velez‐Pardo, C., Jiménez-Del-Río, M., Verschueren, H., Ebinger, G., & Vauquelin, G. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb00287.x · Cited by 77 · see citing works

On the function of neuromelanin

Smythies, J. (1996) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1996.0073 · Cited by 76 · see citing works

Lipoxygenase-Catalyzed Oxidation of Catecholamines

Rosei, M. A., Blarzino, C., Foppoli, C., Mosca, L., & Coccia, R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1454 · Cited by 75 · see citing works

Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains

Nishimura, M., Tomimoto, H., Suenaga, T., Nakamura, S., Namba, Y., Ikeda, K., Akiguchi, I., & Kimura, J. (1994) · Brain Research · doi:10.1016/0006-8993(94)91940-2 · Cited by 73 · see citing works

Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry

Korytowski, W., Sarna, T., Kalyanaraman, B., & Sealy, R. C. (1987) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(87)90152-8 · Cited by 71 · see citing works

An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism

Hayashida, K., Oyanagi, S., Mizutani, Y., & Yokochi, M. (1993) · Acta Neuropathologica · doi:10.1007/bf00334457 · Cited by 67 · see citing works

Anaerobic oxidation of dopamine by iron(III)

El‐Ayaan, U., Herlinger, E., Jameson, R. F., & Linert, W. (1997) · Journal of the Chemical Society Dalton Transactions · doi:10.1039/a701054k · Cited by 66 · see citing works

Mechanism of the Manganese-Catalyzed Autoxidation of Dopamine

Lloyd, R. V. (1995) · Chemical Research in Toxicology · doi:10.1021/tx00043a015 · Cited by 65 · see citing works

Effects of Wild‐Type and Mutated Copper/Zinc Superoxide Dismutase on Neuronal Survival and l ‐DOPA‐Induced Toxicity in Postnatal Midbrain Culture

Mena, M. A., Khan, U., Togasaki, D. M., Sulzer, D. L., Epstein, C. J., & Przedborski, S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010021.x · Cited by 64 · see citing works

The proteasome

Baumeister, W. P., & Lupas, A. N. (1997) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(97)80036-x · Cited by 62 · see citing works

RELATIONSHIP OF GOLGI THIAMINEPYROPHOSPHATASE AND LYSOSOMAL ACID PHOSPHATASE TO NEUROMELANIN AND LIPOFUSCIN IN CEREBRAL NEURONS OF THE AGING RHESUS MONKEY

Barden, H. (1970) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-197004000-00005 · Cited by 61 · see citing works

Covalent Crosslinking of Neurofilament Proteins by Oxidized Catechols as a Potential Mechanism of Lewy Body Formation

Montine, T. J., FARRIS, D. B., & Graham, D. G. (1995) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199505000-00004 · Cited by 57 · see citing works

Lipoxygenase/H2O2-catalyzed oxidation of dihydroxyindoles: synthesis of melanin pigments and study of their antioxidant properties

Blarzino, C., Mosca, L. N., Foppoli, C., Coccia, R., Marco, C. D., & Rosei, M. A. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00225-1 · Cited by 56 · see citing works

Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study

Nishiyama, K., Murayama, S., Shimizu, J., Ohya, Y., Kwak, S., Asayama, K., & Kanazawa, I. (1995) · Acta Neuropathologica · doi:10.1007/bf00571500 · Cited by 54 · see citing works

Biosynthesis, Structure, and Function of Neuromelanin and its Relation to Parkinson's Disease: A Critical Update

d’Ischia, M., & Prota, G. (1997) · Pigment Cell Research · doi:10.1111/j.1600-0749.1997.tb00694.x · Cited by 53 · see citing works

Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome

Fergusson, J., Landon, M., Lowe, J. S., Dawson, S. P., Layfield, R., Hanger, D. P., & Mayer, R. J. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13192-x · Cited by 53 · see citing works

Tyrosine hydroxylase protein in Lewy bodies of parkinsonian and senile brains

Nakashima, S., & Ikuta, F. (1984) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(84)90144-8 · Cited by 52 · see citing works

Monoclonal antibodies to purified cortical lewy bodies recognize the mid‐size neurofilament subunit

Galvin, J. E., Lee, V. M. ‐., Baba, M., Mann, D. M. A., Dickson, D. W., Yamaguchi, H., Schmidt, M. L., Iwatsubo, T., & Trojanowski, J. Q. (1997) · Annals of Neurology · doi:10.1002/ana.410420410 · Cited by 51 · see citing works

The Neuroregulatory Properties of L-DOPA. A Review of the Evidence and Potential Role in the Treatment of Parkinson's Disease

Tedroff, J. (1997) · Reviews in the Neurosciences · doi:10.1515/revneuro.1997.8.3-4.195 · Cited by 47 · see citing works

Endosome-Lysosomes, Ubiquitin and Neurodegeneration

Mayer, R. J., Tipler, C., Arnold, J., László, L., Al-Khedhairy, A. A., Lowe, J. S., & Landon, M. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-0335-0_33 · Cited by 46 · see citing works

Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

Murphy, G. M., Forno, L. S., Higgins, L. S., Scardina, J. M., Eng, L. F., & Cordell, B. (1994) · PubMed Central · Cited by 44 · see citing works

Hydroxyl radical formation via iron-mediated Fenton chemistry is inhibited by methylated catechols

Nappi, A. J., & Vass, E. (1998) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(98)00062-2 · Cited by 44 · see citing works

l ‐DOPA Is a Substrate for Tyrosine Hydroxylase

Haavik, J. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041720.x · Cited by 43 · see citing works

MICROGLIA IN THE MONKEY AND RABBIT RETINA

Vrabec, F. (1970) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-197004000-00004 · Cited by 42 · see citing works

Cysteinyldopamine is not incorporated into neuromelanin

Wakamatsu, K., Ito, S., & Nagatsu, T. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90336-r · Cited by 37 · see citing works

Microtubule-associated protein 5 is a component of Lewy bodies and Lewy neurites in the brainstem and forebrain regions affected in Parkinson's disease

Gai, W. P., Blumbergs, P. C., & Blessing, W. W. (1995) · Acta Neuropathologica · doi:10.1007/s004010050395 · Cited by 37 · see citing works

Melanins From Tetrahydroisoquinolines

Mosca, L., Blarzino, C., Coccia, R., Foppoli, C., & Rosei, M. A. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(97)00211-6 · Cited by 36 · see citing works

Decrease of medullary catecholaminergic neurons in multiple system atrophy and Parkinson's disease and their preservation in amyotrophic lateral sclerosis

Kato, S., Oda, M., Hayashi, H., Shimizu, T., Hayashi, M., Kawata, A., & Tanabe, H. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00155-u · Cited by 36 · see citing works

II. Neuromelanin: A role in MPTP-induced neurotoxicity

D’Amato, R. J., Alexander, G. M., Schwartzman, R. J., Kitt, C. A., Price, D. L., & Snyder, S. H. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90297-9 · Cited by 35 · see citing works

Accumulation of ubiquitinated proteins in mouse neuronal cells induced by oxidative stress

Figueiredo‐Pereira, M. E., Yakushin, S., & Cohen, G. (1997) · Molecular Biology Reports · doi:10.1023/a:1006848405975 · Cited by 34 · see citing works

Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain‐stem in Lewy body disease

Fukuda, T., Tanaka, J., Watabe, K., Numoto, R. T., & Minamitani, M. (1993) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1993.tb03230.x · Cited by 32 · see citing works

Tyrosinase enhances the covalent modification of DNA by dopamine

Stokes, A. H., Brown, B. G., Lee, C. K., Doolittle, D. J., & Vrana, K. E. (1996) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00164-7 · Cited by 32 · see citing works

Deposition of detergent-resistant neurofilaments into Lewy body fibrils

Pollanen, M. S., Bergeron, C., & Weyer, L. (1993) · Brain Research · doi:10.1016/0006-8993(93)91307-e · Cited by 29 · see citing works

Serotonin binding proteins.

Tamir, H. (1982) · Journal of Histochemistry & Cytochemistry · doi:10.1177/30.8.6749975 · Cited by 26 · see citing works

Production of melanin pigments by cytochrome c/H2O2 system

Rosei, M. A., Blarzino, C., Coccia, R., Foppoli, C., Mosca, L., & Cini, C. (1998) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(98)00014-4 · Cited by 26 · see citing works

A kinetic study of the reaction between noradrenaline and iron(III): an example of parallel inner- and outer-sphere electron transfer

El‐Ayaan, U., Jameson, R. F., & Linert, W. (1998) · Journal of the Chemical Society Dalton Transactions · doi:10.1039/a708639c · Cited by 24 · see citing works

SERUM DEPRIVATION INHIBITS GLUTATHIONE DEPLETION-INDUCED DEATH IN EMBRYONIC CORTICAL NEURONS: EVIDENCE AGAINST OXIDATIVE STRESS AS A FINAL COMMON MEDIATOR OF NEURONAL APOPTOSIS

Ratan, R. R., Lee, J. S., & Baraban, J. M. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00115-8 · Cited by 24 · see citing works

Abnormal accumulation of phospholipase C-δ in filamentous inclusions of human neurodegenerative diseases

Shimohama, S., Perry, G. L., Richey, P. L., Takenawa, T., Whitehouse, P. J., Miyoshi, K., Suenaga, T., Matsumoto, S., Nishimura, M., & Kimura, J. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90591-8 · Cited by 23 · see citing works

Lipofuscin-like pigments by autoxidation of polyunsaturated fatty acids in the presence of amine neurotransmitters: the role of malondialdehyde

d’Ischia, M., COSTANTINI, C., & Prota, G. (1996) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(96)00036-0 · Cited by 22 · see citing works

Iron- and peroxide-dependent conjugation of dopamine with cysteine: oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine

Palumbo, A., d’Ischia, M., Misuraca, G., Martino, L. D., & Prota, G. (1995) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(95)00094-r · Cited by 21 · see citing works

Monoamine and Iron-Related Toxicity

Velez‐Pardo, C., Jiménez-Del-Río, M., Ebinger, G., & Vauquelin, G. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(97)00440-0 · Cited by 17 · see citing works

Pheomelanin Production by the Lipoxygenase‐Catalyzed Oxidation of 5‐S‐Cysteinyldopa and 5‐S‐Cysteinyldopamine

Mosca, L. N., Foppoli, C., Coccia, R., & Rosei, M. A. (1996) · Pigment Cell Research · doi:10.1111/j.1600-0749.1996.tb00099.x · Cited by 17 · see citing works

Membrane trafficking in neurons

Holtzman, E. (1992) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(92)90026-h · Cited by 16 · see citing works

Antibody to an abnormal protein in amyotrophic lateral sclerosis identifies Lewy body-like inclusions in ALS and Lewy bodies in Parkinson's disease

Mather, K., Watts, F. Z., Carroll, M. T., Whitehead, P., Swash, M., Cairn, N., & Burke, J. F. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90905-z · Cited by 15 · see citing works

Possible Involvement of Ubiquitination in Neurofilament Degradation

Gou, J. P., & Leterrier, J. F. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2808 · Cited by 15 · see citing works

Multicatalytic proteinase is associated with characteristic oval structures in cortical Lewy bodies: an immunocytochemical study with light and electron microscopy

Masaki, T., Ishiura, S., Sugita, H., & Kwak, S. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90288-7 · Cited by 15 · see citing works

Further observations on MxA-positive Lewy bodies in Parkinson's disease brain tissues

Yamada, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11777-t · Cited by 12 · see citing works

[O2 generation during neuromelanin synthesis. The action of manganese].

Marinho, C. R., & Manso, C. F. (1993) · PubMed · Cited by 11 · see citing works

Production of Melanins by Ceruloplasmin

Rosei, M. A., Foppoli, C., WANG, X. T., Coccia, R., & Mateescu, M. A. (1998) · Pigment Cell Research · doi:10.1111/j.1600-0749.1998.tb00717.x · Cited by 6 · see citing works

The role of iron in brain ageing and neurodegenerative disorders

Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819 · see citing works

Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight

Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., Masood, A., Sofi, M. A., & Ganie, S. A. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.07.025 · Cited by 938 · see citing works

Oxidative stress and Parkinson’s disease

Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878 · see citing works

Dopamine covalently modifies and functionally inactivates parkin

LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722 · see citing works

Complexity of dopamine metabolism

Meiser, J., Weindl, D., & Hiller, K. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-34 · Cited by 665 · see citing works

Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease

Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659 · see citing works

Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade

Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 603 · see citing works

Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease

Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 583 · see citing works

Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons

Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. L. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 530 · see citing works

Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease

Asanuma, M., Miyazaki, I., & Ogawa, N. (2003) · Neurotoxicity Research · doi:10.1007/bf03033137 · Cited by 518 · see citing works

Oxidative stress and inflammation in Parkinson's disease: is there a causal link?

Hald, A., & Lotharius, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.013 · Cited by 506 · see citing works

Protective and toxic roles of dopamine in Parkinson's disease

Segura‐Aguilar, J., Paris, I. B., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 499 · see citing works

Mechanisms of neurodegeneration in Huntington’s disease

Gil‐Mohapel, J., & Rego, A. C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06310.x · Cited by 480 · see citing works

Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles

Sulzer, D. L., Bogulavsky, J. J., Larsen, K. E., Behr, G. G., Karatekin, E., Kleinman, M. H., Turro, N. J., Krantz, D. E., Edwards, R. H., Greene, L. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.11869 · Cited by 460 · see citing works

The need for speed: an update on methamphetamine addiction

Barr, A. M., Panenka, W. J., MacEwan, G. W., Thornton, A. E., Lang, D. J., Honer, W. G., & Lecomte, T. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0635 · Cited by 442 · see citing works

Iron, Neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes

Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401 · see citing works

Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease

Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K. M., Laurie, C. D., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 388 · see citing works

The relevance of iron in the pathogenesis of Parkinson’s disease

Sian‐Hülsmann, J., Mandel, S. A., Youdim, M. B. H., & Riederer, P. F. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 349 · see citing works

Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease

Fedorow, H., Tribl, F., Halliday, G. M., Gerlach, M., Riederer, P. F., & Double, K. L. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.001 · Cited by 347 · see citing works

Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis

Carballo‐Carbajal, I., Laguna, A., Romero‐Giménez, J., Cuadros, T., Bové, J., Martínez‐Vicente, M., Parent, A., González-Sepúlveda, M., Peñuelas, N., Torra, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08858-y · Cited by 345 · see citing works

Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis

Larsen, K. E., Fon, E. A., Hastings, T. G., Edwards, R. H., & Sulzer, D. L. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08951.2002 · Cited by 335 · see citing works

Dopamine, Immunity, and Disease

Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J. R., & Gaskill, P. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 319 · see citing works

Role of dopamine in the pathophysiology of Parkinson’s disease

Zhou, Z.-D., Yi, L.-X., Wang, D. Q., Lim, T. M., & Tan, E.-K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 287 · see citing works

Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine

Bisaglia, M., Mammi, S., & Bubacco, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610893200 · Cited by 303 · see citing works

Progressive fuzzy cation-π assembly of biological catecholamines

Hong, S., Wang, Y., Park, S. Y., & Lee, H. (2018) · Science Advances · doi:10.1126/sciadv.aat7457 · Cited by 295 · see citing works

Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease

Sulzer, D. L., Cassidy, C., Horga, G., Kang, U. J., Fahn, S., Casella, L., Pezzoli, G., Langley, J. A., Hu, X. P., Zucca, F. A., et al. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0047-3 · Cited by 277 · see citing works

Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells

Rideout, H. J., Larsen, K. E., Sulzer, D. L., & Stefanis, L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00474.x · Cited by 274 · see citing works

Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway

Lotharius, J., Falsig, J., van Beek, J., Payne, S., Dringen, R., Brundin, P., & Leist, M. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1746-05.2005 · Cited by 262 · see citing works

Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson's disease

Filomeni, G., Graziani, I., Zio, D. D., Dini, L., Centonze, D., Rotilio, G., & Ciriolo, M. R. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.021 · Cited by 262 · see citing works

Neurodegeneration and neuroprotection in Parkinson disease

Fahn, S., & Sulzer, D. L. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.139 · Cited by 266 · see citing works

Oxidative Stress and Autophagy in Cardiac Disease, Neurological Disorders, Aging and Cancer

Essick, E. E., & Sam, F. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.3.12106 · Cited by 249 · see citing works

Neuromelanin of the Human Substantia Nigra: An Update

Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243 · see citing works

Autophagy in neurons: a review.

Larsen, K. E., & Sulzer, D. L. (2002) · PubMed · doi:10.14670/hh-17.897 · Cited by 242 · see citing works

Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice

Chen, L., Ding, Y., Cagniard, B., Laar, A. D. V., Mortimer, A. D., Chi, W., Hastings, T. G., Kang, U. J., & Zhuang, X. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3602-07.2008 · Cited by 238 · see citing works

Bioactivity of Olive Oil Phenols in Neuroprotection

Angeloni, C., Malaguti, M., Barbalace, M. C., & Hrelia, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112230 · Cited by 237 · see citing works

The role of free radicals in the aging brain and Parkinson’s Disease: Convergence and parallelism

Kumar, H., Lim, H.-W., More, S. V., Kim, B.-W., Koppula, S., Kim, I. S., & Choi, D.-K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130810478 · Cited by 212 · see citing works

Oxidative stress factors in Parkinson’s disease

Dorszewska, J., Kowalska, M., Prendecki, M., Piekut, T., Kozłowska, J., & Kozubski, W. P. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.300980 · Cited by 211 · see citing works

Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration

Petersén, Å. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1243 · Cited by 210 · see citing works

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

Lohr, K. M., Bernstein, A. I., Stout, K. A., Dunn, A. R., Lazo, C. R., Alter, S. P., Wang, M., Li, Y., Fan, X., Hess, E. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402134111 · Cited by 209 · see citing works

Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons

Guillot, T. S., & Miller, G. W. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8059-y · Cited by 201 · see citing works

New Avenues for the Treatment of Huntington’s Disease

Kim, A. M., Lalonde, K. M., Truesdell, A., Welter, P. G., Brocardo, P. S., Rosenstock, T. R., & Gil‐Mohapel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168363 · Cited by 198 · see citing works

Targets for neuroprotection in Parkinson's disease

Yacoubian, T. A., & Standaert, D. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.009 · Cited by 189 · see citing works

Bacterial Artificial Chromosome Transgenic Mice Expressing a Truncated Mutant Parkin Exhibit Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Degeneration, and Accumulation of Proteinase K-Resistant α-Synuclein

Lu, X., Fleming, S. M., Meurers, B. H., Ackerson, L. C., Mortazavi, F., Lo, V., Hernandez, D., Sulzer, D., Jackson, G. R., Maidment, N. T., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5351-08.2009 · Cited by 177 · see citing works

α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration

Mosharov, E. V., Staal, R. G. W., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M. H., Troyer, M. D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0519-06.2006 · Cited by 165 · see citing works

Neuroprotective Effect of Kaempferol against a 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Mouse Model of Parkinson's Disease

Li, S., & Pu, X. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1291 · Cited by 157 · see citing works

Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse

Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148 · see citing works

A Drosophila Model of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine

Sang, T., Chang, H.-Y., Lawless, G. M., Ratnaparkhi, A., Mee, L., Ackerson, L. C., Maidment, N. T., Krantz, D. E., & Jackson, G. R. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4810-06.2007 · Cited by 146 · see citing works

Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities

Sbodio, J. I., Snyder, S. H., & Paul, B. D. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7321 · Cited by 143 · see citing works

Iron overload: Effects on cellular biochemistry

Nogueira, L. S., Oliveira, M. M., Pessoa, M. T., & Barbosa, L. A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.029 · Cited by 144 · see citing works

Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease

Dunn, A. R., Stout, K. A., Ozawa, M., Lohr, K. M., Hoffman, C. A., Bernstein, A. I., Li, Y., Wang, M., Sgobio, C., Sastry, N. G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616892114 · Cited by 138 · see citing works

Immunomodulatory Effects Mediated by Dopamine

Arreola, R., Álvarez-Herrera, S., Pérez‐Sánchez, G., Becerril‐Villanueva, E., Cruz-Fuentes, C. S., Flores-Gutiérrez, E. O., Garcés-Alvarez, M. E., de la Cruz-Aguilera, D. L., Medina‐Rivero, E., Hurtado‐Alvarado, G., et al. (2016) · Journal of Immunology Research · doi:10.1155/2016/3160486 · Cited by 137 · see citing works

The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease

Cuadrado, A., Moreno-Murciano, P., & Pedraza‐Chaverrí, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/13543780802716501 · Cited by 135 · see citing works

Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration

Zhang, S., Wang, R., & Wang, G. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00454 · Cited by 133 · see citing works

Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease

Stone, D. K., Reynolds, A. D., Mosley, R. L., & Gendelman, H. E. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2460 · Cited by 130 · see citing works

The Reaction of α-Synuclein with Tyrosinase

Tessari, I., Bisaglia, M., Valle, F., Samorı̀, B., Bergantino, E., Mammi, S., & Bubacco, L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709014200 · Cited by 132 · see citing works

Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action

Ostadkarampour, M., & Putnins, E. E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.676239 · Cited by 133 · see citing works

Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells

Fornai, F., Lenzi, P., Gesi, M., Soldani, P., Ferrucci, M., Lazzeri, G., Capobianco, L., Battaglia, G., Blasi, A. D., Nicoletti, F., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02137.x · Cited by 127 · see citing works

An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition

Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124 · see citing works

Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease

Greggio, E., Bergantino, E., Carter, D., Ahmad, R., Costin, G., Hearing, V. J., Clarimón, J., Singleton, A., Eerola, J., Hellström, O., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03019.x · Cited by 123 · see citing works

Neuroprotective effects of zonisamide target astrocyte

Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J. J., Kimoto, N., Kikkawa, Y., Takeshima, M., Miyoshi, K., & Murata, M. (2009) · Annals of Neurology · doi:10.1002/ana.21885 · Cited by 117 · see citing works

Physiological Phenotype and Vulnerability in Parkinson's DiseasePreprint

Surmeier, D. J., Guzmán, J. N., Sánchez, J. A., & Schumacker, P. T. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009290 · Cited by 115 · see citing works

l-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?

Lipski, J., Nisticò, R., Berretta, N., Guatteo, E., Bernardi, G., & Mercuri, N. B. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.06.005 · Cited by 116 · see citing works

Plasma selenium is positively related to performance in neurological tasks assessing coordination and motor speed

Shahar, A., Patel, K. V., Semba, R. D., Bandinelli, S., Shahar, D. R., Ferrucci, L., & Guralnik, J. M. (2010) · Movement Disorders · doi:10.1002/mds.23218 · Cited by 108 · see citing works

Life span pigmentation changes of the substantia nigra detected by neuromelanin‐sensitive MRI

Xing, Y., Sapuan, A. H., Dineen, R. A., & Auer, D. P. (2018) · Movement Disorders · doi:10.1002/mds.27502 · Cited by 103 · see citing works

The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration

Mor, D. E., Daniels, M. J., & Ischiropoulos, H. (2019) · Movement Disorders · doi:10.1002/mds.27607 · Cited by 103 · see citing works

Revisiting the Paraquat-Induced Sporadic Parkinson’s Disease-Like Model

Candia, S. B., Zolezzi, J. M., & Inestrosa, N. C. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1148-z · Cited by 102 · see citing works

Mitochondrial dysfunction in Parkinson’s disease

Fukae, J., Mizuno, Y., & Hattori, N. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.12.002 · Cited by 100 · see citing works

Mitochondrial Dysfunction and Oxidative Stress in Parkinson’s Disease

Onyango, I. G. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9482-y · Cited by 100 · see citing works

Fast and enhanced electrochemical sensing of dopamine at cost-effective poly(DL-phenylalanine) based graphite electrode

Hareesha, N., & Manjunatha, J. G. (2020) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2020.114533 · Cited by 101 · see citing works

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice

Longo, F., Mercatelli, D., Novello, S., Arcuri, L., Brugnoli, A., Vincenzi, F., Russo, I., Berti, G., Mabrouk, O. S., Kennedy, R. T., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0426-8 · Cited by 99 · see citing works

Dopamine signalling in locusts and other insects

Verlinden, H. (2018) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2018.04.005 · Cited by 100 · see citing works

DJ-1 protects against dopamine toxicity

Lev, N., Ickowicz, D., Barhum, Y., Lev, S., Melamed, E., & Offen, D. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0134-4 · Cited by 96 · see citing works

Molecular Effects of L-dopa Therapy in Parkinson’s Disease

Dorszewska, J., Prendecki, M., Lianeri, M., & Kozubski, W. P. (2014) · Current Genomics · doi:10.2174/1389202914666131210213042 · Cited by 96 · see citing works

Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders

Wise, R. M., Wagener, A., Fietzek, U. M., Klopstock, T., Mosharov, E. V., Zucca, F. A., Sulzer, D. L., Zecca, L., & Burbulla, L. F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105920 · Cited by 95 · see citing works

Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity

Miyazaki, I., Asanuma, M., Kikkawa, Y., Takeshima, M., Murakami, S., Miyoshi, K., Sogawa, N., & Kita, T. (2010) · Glia · doi:10.1002/glia.21112 · Cited by 96 · see citing works

Reduced vesicular storage of dopamine exacerbates methamphetamine‐induced neurodegeneration and astrogliosis

Guillot, T. S., Shepherd, K. R., Richardson, J. R., Wang, M. Z., Li, Y., Emson, P. C., & Miller, G. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05568.x · Cited by 94 · see citing works

Childhood Blood Lead Levels and Symptoms of Attention Deficit Hyperactivity Disorder (ADHD): A Cross-Sectional Study of Mexican Children

Huang, S., Hu, H., Sánchez, B. N., Peterson, K. E., Ettinger, A. S., Lamadrid‐Figueroa, H., Schnaas, L., Mercado‐García, A., Wright, R. O., Basu, N., et al. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1510067 · Cited by 94 · see citing works

Oxidatively generated DNA damage after Cu(II) catalysis of dopamine and related catecholamine neurotransmitters and neurotoxins: Role of reactive oxygen species

Spencer, W. A., Jeyabalan, J., Kichambre, S., & Gupta, R. C. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.10.693 · Cited by 92 · see citing works

Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD

Esteves, A. R., Arduíno, D. M., Silva, D. F., Oliveira, C. R., & Cardoso, S. M. (2011) · Parkinson s Disease · doi:10.4061/2011/693761 · Cited by 89 · see citing works

Dopamine-modified TiO 2 monolith-assisted LDI MS imaging for simultaneous localization of small metabolites and lipids in mouse brain tissue with enhanced detection selectivity and sensitivity

Wu, Q., Chu, J. L., Rubakhin, S. S., Gillette, M. U., & Sweedler, J. V. (2017) · Chemical Science · doi:10.1039/c7sc00937b · Cited by 89 · see citing works

Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress

Limanaqi, F., Gambardella, S., Biagioni, F., Busceti, C., & Fornai, F. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4982453 · Cited by 84 · see citing works

The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson’s Disease

Minakaki, G., Krainc, D., & Burbulla, L. F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580634 · Cited by 83 · see citing works

Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses

Wengler, K., He, X., Abi‐Dargham, A., & Horga, G. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116457 · Cited by 79 · see citing works

Glial Modulators as Potential Treatments of Psychostimulant Abuse

Beardsley, P. M., & Hauser, K. F. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00001-9 · Cited by 82 · see citing works

Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?

Bisaglia, M., Filograna, R., Beltramini, M., & Bubacco, L. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2013.12.009 · Cited by 80 · see citing works

Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?

Post, M. R., Lieberman, O. J., & Mosharov, E. V. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00161 · Cited by 79 · see citing works

Oxidative stress and Parkinson's disease

Jenner, P. G. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83024-7 · Cited by 79 · see citing works

Dopamine-Induced Behavioral Changes and Oxidative Stress in Methamphetamine-Induced Neurotoxicity

Kita, T., Miyazaki, I., Asanuma, M., Takeshima, M., & Wagner, G. C. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)88003-3 · Cited by 77 · see citing works

Alpha‐synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation

Bellucci, A., Collo, G., Sarnico, I., Battistin, L., Missale, C., & Spano, P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05406.x · Cited by 77 · see citing works

Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite

Bruning, J. M., Wang, Y., Oltrabella, F., Tian, B., Kholodar, S. A., Liu, H., Bhattacharya, P., Guo, S., Holton, J. M., Fletterick, R. J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.002 · Cited by 78 · see citing works

Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism.

Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J. J., & Ogawa, N. (2004) · PubMed · doi:10.18926/amo/32105 · Cited by 76 · see citing works

l ‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?

Carta, A. R., Mulas, G., Bortolanza, M., Duarte, T. T., Pillai, E., Fisone, G., Raisman‐Vozari, R., & Bel, E. A. D. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13482 · Cited by 76 · see citing works

The Positive Role and Mechanism of Herbal Medicine in Parkinson’s Disease

Yin, R. L., Xue, J., Tan, Y., Fang, C., Hu, C., Yang, Q., Mei, X., & Qi, D. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9923331 · Cited by 79 · see citing works

The vesicular monoamine transporter 2: An underexplored pharmacological target

Bernstein, A. I., Stout, K. A., & Miller, G. W. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2013.12.003 · Cited by 74 · see citing works

Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat

Bustamante, D., You, Z., Castel, M., Johansson, S., Goiny, M., Terenius, L. Y., Hökfelt, T. G. M., & Herrera‐Marschitz, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01171.x · Cited by 74 · see citing works

Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells

Machida, Y., Chiba, T., Takayanagi, A., Tanaka, Y., Asanuma, M., Ogawa, N., Koyama, A., Iwatsubo, T., Ito, S., Jansen, P. H., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.04.124 · Cited by 73 · see citing works

Nuclear Factor Erythroid 2 - Related Factor 2 Signaling in Parkinson Disease: A Promising Multi Therapeutic Target Against Oxidative Stress, Neuroinflammation and Cell Death

Kumar, H., Koppula, S., Kim, I., More, S. V., Kim, B.-W., & Choi, D. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311211080012 · Cited by 70 · see citing works

Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus

Taylor, T. N., Alter, S. P., Wang, M., Goldstein, D. S., & Miller, G. W. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.033 · Cited by 71 · see citing works

5′ and 3′ region variability in the dopamine transporter gene ( SLC6A3 ), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study

Kelada, S. N., Checkoway, H., Kardia, S. L. R., Carlson, C. S., Costa‐Mallen, P., Eaton, D. L., Firestone, J. A., Powers, K. M., Swanson, P. D., Franklin, G. M., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl247 · Cited by 71 · see citing works

Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review

Kostrzewa, R. M., & Segura‐Aguilar, J. (2003) · Neurotoxicity Research · doi:10.1007/bf03033166 · Cited by 68 · see citing works

Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease

Asanuma, M., Miyazaki, I., & Ogawa, N. (2003) · Neurotoxicity Research · doi:10.1007/bf03033137 · Cited by 518 · see citing works

Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules

宮﨑, 育. (n.d.) · Institutional Repositories DataBase (IRDB)

Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease

Jicha, G. A., Berenfeld, B., & Davies, P. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990315)55:6 · Cited by 123 · see citing works

Dopamine oxidation to neuromelanin and neurotoxic metabolites

Segura‐Aguilar, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822120-4.00002-2 · Cited by 7 · see citing works

メタンフェタミン誘発ドパミン神経毒性はキノン体形成関連分子により調節されている

Miyazaki, I. (2006) · Okayama University Scientific Achievement Repository (Okayama University)